Search Results

Your search for Elizabeth A. Comen, MD, and Andrew D. Seidman, MD,Elizabeth A. Comen, MD, and Andrew D. Seidman, MD matches 2 pages

Showing 1 - 2

By Elizabeth A. Comen, MD, and Andrew D. Seidman, MD / May 25, 2015

Increased Risk of Secondary Bone Marrow Neoplasia After Adjuvant Breast Cancer Treatment: Risk/Benefit Analysis and Biologic Insights

Ever since the early application of adjuvant chemotherapy for breast cancer decades ago, it has been recognized that there is always a price to pay for its success in reducing breast cancer mortality. Most of that “cost” is commonly considered in terms of the potential morbid short- and long-term...

breast cancer

By Matthew Stenger / May 25, 2015

Higher-Than-Expected Incidence of Marrow Neoplasms After Adjuvant Therapy for Breast Cancer

In a study reported in the Journal of Clinical Oncology, Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues found a low but higher-than-expected incidence of marrow neoplasms in patients receiving adjuvant radiation therapy or chemotherapy...

Nov

Today In Oncology

Search Results

Your search for Elizabeth A. Comen, MD, and Andrew D. Seidman, MD,Elizabeth A. Comen, MD, and Andrew D. Seidman, MD matches 2 pages

Increased Risk of Secondary Bone Marrow Neoplasia After Adjuvant Breast Cancer Treatment: Risk/Benefit Analysis and Biologic Insights

Higher-Than-Expected Incidence of Marrow Neoplasms After Adjuvant Therapy for Breast Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC